Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

active_not_recruiting133%
recruiting267%

Recent Activity

3 active trials
Showing 3 of 3
recruitingphase_2

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

NCT07006077
active_not_recruitingphase_1

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

NCT05914376
recruitingnot_applicable

A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.

NCT07185243

Clinical Trials (3)

Showing 3 of 3 trials
NCT07006077Phase 2

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

Recruiting
NCT05914376Phase 1

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors

Active Not Recruiting
NCT07185243Not Applicable

A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3